✦ LIBER ✦

Factors influencing the response of non-small cell lung cancer (NSCLC) to combination chemotherapy with bleomycin (B), etoposide (E) and cis-platinum (P)

Book ID: 123042013
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 179 KB
Volume: 2
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(86)80499-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors for response to chemo

Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC)

✍ Borges, M.; Sculier, J.P.; Paesmans, M.; Richez, M.; Bureau, G.; Dabouis, G.; Le 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 853 KB

P-539 Response to a combination of S-1 a

P-539 Response to a combination of S-1 and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC)

✍ Sugawara, Shunichi; Nakai, Yushi; Ichinose, Yukito; Yoshimori, Kozo; Sakai, Hiro 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Eg5 expression is closely correlated wit

Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy

✍ Saijo, Takamoto; Ishii, Genichiro; Ochiai, Atsushi; Yoh, Kiyotaka; Goto, Koichi; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 363 KB

1249 Combination of platinum standard fi

1249 Combination of platinum standard first front line chemotherapy and anti-idiotype 1E10/aluminum vaccine in patients with advanced non- small- cell lung cancer (NSCLC)

✍ A. Macias; D. Toledo; E. Santiesteban; F. Aguirre; X. Popa; A. Vazquez; Z. Mazor 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Combination chemotherapy with mitomycin-

Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer

✍ Niell, Harvey B. ;Griffin, John P. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

The drug combination of mitomycin-C, cisplatin, and vinblastine was administered to 30 patients with stage III non-small-cell lung cancer. All patients had a performance status of 50% or greater, had evaluable disease, and had not received previous chemotherapy. The overall response rate was 37% wit

P-38 Retrospective analysis of combined

P-38 Retrospective analysis of combined cisplatin (P) and etoposide (E) regimen tolerability in the elderly (≥65 years) and non-elderly (<65 years) patients (pts) with advanced non-small-cell lung cancer (NSCLC)

✍ Gorbounova, Vera; Besova, Natalia; Mindra, Natalia; Markovich, Alla 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 194 KB